Friday, July 10, 2026

pharma · Multiple Myeloma · Recurrent glioblastoma

Oncopeptides AB (publ)

Oncopeptides AB (publ) clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Stockholm, SE HQ
2000 Founded
85 Employees
EMA registrant Type
Company details
Status
Public
HQ
Stockholm, SE
Founded
2000
Employees
85
Programs
2
Drugs
2
Patents
0
Intelligence · Clinical Programs

Oncopeptides AB (publ) projects

1 ClinicalTrials.gov programs sponsored by Oncopeptides AB (publ).

Oncopeptides AB (publ) has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Melflufen

    Oncopeptides AB (publ)

    Multiple Myeloma

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Oncopeptides AB (publ) have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.